Company intelligence / Profile preview

AsclepiX Therapeutics

Baltimore, Maryland, United Statesasclepix.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

AXT107 is a synthetic collagen IV-derived peptide that inhibits neovascularization by targeting VEGFR2 and activating Tie2 pathways. It forms an intravitreal self-forming gel depot allowing potentially yearly dosing versus frequent injections required by current anti-VEGF therapies. Animal models show superiority over Eylea with longer durability. The Phase1/2a CONGO trial has dosed patients with diabetic macular edema demonstrating safety and bioactivity.

Therapeutic areas: OphthalmologyOncology
Modalities: Peptide therapeuticsComputational biology-driven peptide discovery platformIntravitreal self-forming gel depot delivery system
Industry: Biotech

Drug pipeline

1 asset

gersizangitide

Beyond the preview

Go deeper on AsclepiX Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AsclepiX Therapeutics.

Explore the full profile